Guangdong Hongjing Optoelectronic Technology Inc.
301479
LTECH
832110
FZFM
920082
4
JiangSu Jinji Industrial
300798
5
Shandong Nanshan Fashion Sci-Tech
300918
US Stock MarketDetailed Quotes
PMN ProMIS Neurosciences
- 0.730
- -0.001-0.14%
Close Mar 18 16:00 ET
23.86MMarket Cap18.25P/E (TTM)
0.766High0.700Low21.72KVolume0.730Open0.731Pre Close15.79KTurnover0.12%Turnover RatioLossP/E (Static)32.69MShares2.61052wk High3.29P/B12.75MFloat Cap0.62152wk Low--Dividend TTM17.46MShs Float9.800Historical High--Div YieldTTM9.03%Amplitude0.621Historical Low0.726Avg Price1Lot Size
ProMIS Neurosciences Stock Forum
Sign in to post a comment
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease
5 minutes ago, 4:00 AM PST
Via GlobeNewswire
PMN
Share
CAMBRIDGE, Massachusetts, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b clinical trial (PRECISE-AD) evaluating its lead therapeutic...
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease
5 minutes ago, 4:00 AM PST
Via GlobeNewswire
PMN
Share
CAMBRIDGE, Massachusetts, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b clinical trial (PRECISE-AD) evaluating its lead therapeutic...
1
$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
28
9
7
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's dise...
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's dise...
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
ProMIS Neurosciences Inc. (Nasdaq: PMN) presented preclinical data at the 2024 Alzheimer's Association International Conference (AAIC) supporting their novel approach to optimizing an Alzheimer's disease (AD) vaccine. The company's proprietary computational platform identified four AβO-restricte...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
ProMIS Neurosciences Inc. (Nasdaq: PMN) presented preclinical data at the 2024 Alzheimer's Association International Conference (AAIC) supporting their novel approach to optimizing an Alzheimer's disease (AD) vaccine. The company's proprietary computational platform identified four AβO-restricte...
2
$ProMIS Neurosciences (PMN.US)$
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
▪️ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:
▪️A favorable safety profile and tolerability across four ascending dose levels
▪️Dose-dependent levels of PMN310 antibody in cerebrospinal fluid (CSF)
Potenti...
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
▪️ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:
▪️A favorable safety profile and tolerability across four ascending dose levels
▪️Dose-dependent levels of PMN310 antibody in cerebrospinal fluid (CSF)
Potenti...
3
6
No comment yet
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
Lnova : thanks for posting
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")